Abstract | OBJECTIVE: Oncogenic alternation in RET is one of the important targets of non-small cell lung cancer (NSCLC). Pralsetinib has shown great efficacy in RET fusion-positive NSCLC, but a series of adverse reactions will inevitably occur in the meantime. We aimed to explore the clinical characteristics of patients with pneumonia and recognition it in early stage, so patients could longer benefit from pralsetinib. METHODS: RESULTS: A total of 8 patients with pneumonia were included in the study, most of which were non-smoking female patients and the main fusion gene was KIF5B (87.5%), which was consistent with the general characteristics of RET fusion population. The median occurrence time of pralsetinib-associated pneumonia was 2.15 (range 1.1-6.63) months. All patients were infected by opportunistic pathogens, and the most common pathogen was human herpesviruses and pneumospora yerbii. Fever was always the first symptom, and timely anti-infective treatment including antibiotics, antiviral drugs, and antifungal drugs was effective. Until February 28, 2023, the median follow-up time was 18.7 months, the mean PFS of patients was 17.4 months, and the median PFS was not reached. Fortunately, patients who restarted pralsetinib after infection control continued to benefit. CONCLUSIONS:
|
Authors | Ming Gao, Xia Zhang, Huan Yan, Decong Sun, Xuejiao Yang, Fang Yuan, Yanfang Ju, Lijie Wang, Jinliang Wang, Wei Zhao, Dong Zhang, Lin Li, Xiaoyun Xu, Junxun Ma, Yi Hu, Xiaotao Zhang |
Journal | Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
(Support Care Cancer)
Vol. 31
Issue 12
Pg. 671
(Nov 04 2023)
ISSN: 1433-7339 [Electronic] Germany |
PMID | 37924363
(Publication Type: Multicenter Study, Journal Article)
|
Copyright | © 2023. The Author(s). |
Chemical References |
- pralsetinib
- Pyridines
- RET protein, human
- Proto-Oncogene Proteins c-ret
|
Topics |
- Humans
- Female
- Carcinoma, Non-Small-Cell Lung
(drug therapy)
- Lung Neoplasms
(drug therapy, genetics)
- Retrospective Studies
- Pyridines
(therapeutic use)
- Proto-Oncogene Proteins c-ret
(genetics, therapeutic use)
|